Insulin Resistance: Implications for Nutrition, Oncology, and Diabetes Management-An Updated Review

Background: Insulin resistance—diminished tissue responsiveness to insulin in liver, skeletal muscle, and adipose tissue—drives dysglycemia, dyslipidemia, hypertension, and proinflammatory/prothrombotic states, predisposing to metabolic syndrome, NAFLD/MASLD, and type 2 diabetes (T2D). Clinical diagnosis lacks a single standard; research-grade clamps are impractical, so surrogate indices (HOMAIR, QUICKI, triglyceride/HDL-C ratio) and metabolic syndrome criteria are used. Aim: To provide an updated, interdisciplinary synthesis of insulin resistance with practical implications for nutrition counseling, oncology co-management, and diabetes care, spanning etiology, epidemiology, pathophysiology, evaluation, treatment, complications, prognosis, and team-based delivery. Methods: Narrative integration of current concepts presented in the review, including tissue-specific mechanisms (DAG/PKC signaling defects, de novo lipogenesis, lipotoxicity), population trends (NHANES-based estimates), diagnostic surrogates, and therapeutic modalities (lifestyle, pharmacotherapy, bariatric surgery), framed for interprofessional application. Results: Acquired drivers—visceral adiposity, caloric excess, physical inactivity, aging, and select medications—predominate, with genetic syndromes and receptor-level defects contributing in a minority. Prevalence has risen substantially in young adults. Practical assessment leverages fasting and dynamic indices and harmonized metabolic syndrome criteria. Lifestyle intervention (dietary energy reduction and lower glycemic load plus structured exercise) is first-line and cost-effective; DPP/DPPOS show substantial diabetes risk reduction. Metformin, GLP1 and dual GIP/GLP1 agonists, SGLT2 inhibitors, and selective use of TZDs/DPP4s complement lifestyle; bariatric/metabolic surgery offers durable benefit in eligible patients. Complications span micro- and macrovascular disease and NAFLD; prognosis is modifiable, with 5–10% weight loss yielding clinically meaningful risk reduction. Conclusion: A staged, lifestyle-first strategy, augmented by modern pharmacotherapy and surgery when indicated, and delivered by an interprofessional team, can curb progression to T2D and cardiovascular disease while improving quality of life across metabolic and oncology care pathways.